Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

PURPOSE: The sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin may reduce the incidence of obstructive sleep apnea (OSA) in patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of VERTIS CV, the CV outcome trial for the SGLT2i ertugliflozin conducted in a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., Yaggi, Henry Klar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Sleep Breathing Physiology and Disorders • Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212814/
https://www.ncbi.nlm.nih.gov/pubmed/35596030
http://dx.doi.org/10.1007/s11325-022-02594-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212814/
https://www.ncbi.nlm.nih.gov/pubmed/35596030
http://dx.doi.org/10.1007/s11325-022-02594-2

Ejemplares similares